Daniel R. Marshak, Ph.D., is an executive in the biotechnology industry and a former academic research scientist. He serves on the Board of Directors for the Tecan Group (Swiss SIX:TECN) and for InVivo Therapeutics (NASDAQ:NVIV). He also serves as a Director for private companies, LifeVault Bio Inc.(dba GoodCell), Elevian Inc., RareCyte, Inc. and Otoro Energy, Inc. Dr. Marshak is a consultant to 5AM Ventures and Prime Movers Lab, and he is an advisor to Catalent (NYSE:CTLT) and to Phase Scientific International, Ltd. in Hong Kong as Chief Technology Officer. He has recently worked with RADx, a program to develop diagnostics rapidly for COVID-19 sponsored by the National Institutes of Health.
Dr. Marshak previously served as Senior Vice President & Chief Scientific Officer for PerkinElmer Inc. (NYSE:PKI) and spent several years in Shanghai as PerkinElmer’s President, Greater China and then President, Emerging Diagnostics. Previously, he was Vice President and Chief Technology Officer, Biotechnology, for Cambrex Corporation (NYSE:CBM) and Senior Vice President and Chief Technology Officer for Osiris Therapeutics, Inc.
In academics, Dr. Marshak held an appointment as adjunct Associate Professor at the Johns Hopkins University School of Medicine and earlier as Senior Staff Investigator at the Cold Spring Harbor Laboratory in New York and concurrently Assistant Professor at the State University of New York, Stony Brook. Dr. Marshak received his Bachelor of Arts degree in Biochemical Sciences from Harvard University, and he holds a Ph.D. degree in biochemistry and cell biology from The Rockefeller University in New York. He did postdoctoral work in the Howard Hughes Medical Institute at Vanderbilt University School of Medicine and as a Pharmacology Research Associate Training Fellow at the National Institutes of Health. He is the co-author of more than 100 research papers, editor of several monographs, and co-inventor on 12 issued U.S. patents.